Welcome to our dedicated page for Aptevo Therapeutics SEC filings (Ticker: APVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aptevo Therapeutics Inc. filings document the regulatory record of a clinical-stage biotechnology company developing immune-oncology candidates based on ADAPTIR and ADAPTIR-FLEX platforms. Its 8-K reports record clinical updates for mipletamig in acute myeloid leukemia, annual financial results, material agreements, executive and board changes, and other public-company events.
The company’s proxy and registration filings disclose shareholder voting matters, proposed charter and administrative amendments, Nasdaq share-issuance approvals, common-stock financing arrangements, and capital-structure information related to its standby equity purchase agreement. These filings also provide formal context for governance, securities issuance mechanics, and the funding disclosures associated with Aptevo’s oncology pipeline.
Schedule 13G filing for Aptevo Therapeutics Inc. (NASDAQ: APVO) discloses that a group of affiliated Yorkville entities, led by YA II PN, Ltd., now beneficially owns 357,842 common shares, equal to 9.99 % of the outstanding stock. The position consists entirely of shares that the investors have the right to acquire pursuant to a $25 million Standby Equity Purchase Agreement (SEPA) executed on 16 June 2025. The SEPA prohibits Aptevo from issuing additional shares to the group if doing so would push their aggregate ownership above the 9.99 % threshold.
- Voting/Dispositive power: 0 shares sole; 357,842 shares shared.
- Outstanding shares basis: 3,224,156 shares reported by the issuer on 20 June 2025 plus the 357,842 acquisition rights held by YA II.
- Reporting persons: YA II PN, YA Global Investments II (U.S.), Yorkville Advisors Global LP, related GPs, Mark Angelo, and SC-Sigma Global Partners.